Business Context and Reporting Period
Perspective Therapeutics, Inc. (CATX) is a radiopharmaceutical development company focused on targeted alpha therapy (TAT) using Lead-212 isotopes. This Form 10-Q covers the quarterly period ended March 31, 2026. The Company is a non-accelerated filer and a smaller reporting company. It operates a single segment dedicated to radiopharmaceutical development and has no commercial product revenue, relying on grant funding and equity financing.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Grant Revenue | $76 | $342 |
| Total Operating Expenses | $28,357 | $22,174 |
| Net Loss | $(26,189) | $(18,177) |
| Cash and Cash Equivalents | $53,972 | $44,406 |
| Short-term Investments | $216,957 | $114,108 |
| Total Liquidity (Cash + Investments) | $270,929 | $158,514 |
| Net Cash Used in Operating Activities | $(31,468) | $(21,582) |
| Net Cash Provided by Financing Activities | $164,364 | $9,973 |
Debt and Liabilities: Total liabilities were $63.3 million as of March 31, 2026. This includes a note payable of $1.6 million (current portion $56k) and deferred income of $26.6 million related to the Lantheus Option Agreement. There are no significant long-term debt obligations other than the note payable and lease liabilities.
Material Changes vs. Prior Period
- Revenue: Grant revenue decreased by $266,000 (78%) compared to Q1 2025, reflecting the completion of specific NIH-funded work.
- Operating Expenses: Total operating expenses increased by $6.2 million (28%). Research and Development (R&D) expenses rose by $7.0 million to $21.4 million, driven by increased personnel costs, share-based compensation, and spending on clinical trials and manufacturing. General and Administrative (G&A) expenses decreased by $0.9 million to $7.0 million due to lower professional fees.
- Liquidity: Total cash and short-term investments increased significantly by approximately $112 million, primarily due to a $175 million gross proceeds underwritten offering in February 2026.
- Investing Activities: Net cash used in investing activities surged to $109.6 million (from $5.6 million in Q1 2025) due to $150.3 million in purchases of available-for-sale securities and $6.9 million in property and equipment additions.
Guidance, Outlook, and Risks
Outlook and Guidance: Management believes its liquidity of $270.9 million is sufficient to fund planned operations into late 2027. The Company anticipates a significant increase in expenses, particularly in R&D, as it advances clinical assets (VMT-α-NET, VMT01, PSV359) and expands manufacturing capabilities. No specific financial guidance for future quarters was provided.
Management Commentary:
- Clinical Progress: VMT-α-NET (neuroendocrine tumors) has completed dose escalation in Cohort 3 (6.0 mCi) and opened Cohort 4. Interim data showed no dose-limiting toxicities and objective responses in 72% of patients in Cohort 1 and 2. VMT01 (melanoma) is exploring lower dose levels (1.5 mCi) and combination therapy with nivolumab. PSV359 (solid tumors) has treated 9 patients in Cohorts 1 and 2 and opened Cohort 3.
- Manufacturing: The Company is expanding facilities in Chicago and Los Angeles with a $34.4 million commitment to a general contractor and a €49.0 million agreement with Comecer for equipment. The Somerset, NJ facility is operational with capacity for Phase 3 activities.
Risks and Contingencies:
- Capital Needs: The Company expects to require additional capital to achieve profitability and may need to raise funds sooner than anticipated if expenses exceed projections.
- Regulatory and Clinical Risks: Risks include the potential for clinical trial failures, delays in regulatory approvals (FDA), and the possibility that interim data may not be confirmed.
- Supply Chain: The Company has a "take-or-pay" commitment to purchase approximately $9.9 million of Thorium-228 from the U.S. Department of Energy. Potential tariffs on imported equipment and materials are being monitored.
- Legal: The Company is in settlement negotiations regarding a stockholder proxy statement lawsuit, with an estimated liability capped at $0.2 million.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "late 2027" funding estimate given the significant increase in R&D burn rate ($21.4M in one quarter).
- Capital Raise Dilution: Review the terms of the February 2026 offering (39.6M shares + 6.6M pre-funded warrants) and its impact on existing shareholder dilution.
- Clinical Data Confirmation: Monitor upcoming data readouts for VMT-α-NET and VMT01 to confirm the durability of responses and safety profiles reported in interim data.
- Manufacturing CapEx: Track the execution of the $34.4 million facility modification contracts and the €49.0 million equipment purchase to ensure they align with the projected timeline for commercial readiness.
- Deferred Income Recognition: Monitor the amortization schedule of the $26.6 million deferred income from the Lantheus agreement to understand future non-operating income impacts.